ArticleJournal of personalized medicine2020

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.

Armando Orlandi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.